Literature DB >> 7821277

Neuroprotective effect of ketamine administered after status epilepticus onset.

D G Fujikawa1.   

Abstract

We investigated the neuroprotective effect of the noncompetitive N-methyl-D-asparatate (NMDA) antagonist ketamine when administered after onset of lithium-pilocarpine-induced status epilepticus (SE). Seizures were induced in Wistar rats with lithium chloride (3 mEq/kg) and pilocarpine (PC) (30-60 mg/kg intraperitoneally, i.p.). Fifteen minutes after SE onset, either ketamine 100 mg/kg or normal saline was injected i.p., and 3 h after SE onset atropine, diazepam (DZP), and phenobarbital (PB) were administered i.p. to terminate the seizures. Twenty-four hours later, rats underwent brain perfusion-fixation, with subsequent brain processing for light-microscopic examination. Rats adminstered saline (n = 5) had neuronal damage in 24 of 25 brain regions examined. Rats administered ketamine (n = 7) had significant neuroprotection in 22 of 24 damaged regions. Ketamine reduced the amplitude of seizure discharges, and in 3 rats EEG seizure activity ceased in 30 min; none of these rats had neuronal damage. In the other 4 rats, EEG seizure discharges persisted > 90 min; in these animals, 21 of 24 damaged regions were protected. In contrast, rats with 1-h high-dose PC-induced SE (400 mg/kg i.p. without lithium chloride preadministration) had 14 damaged regions, of which 7 were significantly different from the undamaged regions of the ketamine subgroup with persistent electrographic seizures. Thus, ketamine is remarkably neuroprotective when administered after onset of SE, whether or not seizure discharges are eliminated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7821277     DOI: 10.1111/j.1528-1157.1995.tb00979.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  38 in total

1.  COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia.

Authors:  Elena A Tukhovskaya; Alexey Yu Yukin; Oksana N Khokhlova; Arkady N Murashev; Michael P Vitek
Journal:  J Neurosci Res       Date:  2009-02-15       Impact factor: 4.164

2.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

3.  Down-regulated expression of aquaporin-4 in the cerebellum after status epilepticus.

Authors:  Hui Tang; Chuan Shao; Jiaquan He
Journal:  Cogn Neurodyn       Date:  2016-11-14       Impact factor: 5.082

4.  Convulsive status epilepticus duration as determinant for epileptogenesis and interictal discharge generation in the rat limbic system.

Authors:  Aleksandra Bortel; Maxime Lévesque; Giuseppe Biagini; Jean Gotman; Massimo Avoli
Journal:  Neurobiol Dis       Date:  2010-08-01       Impact factor: 5.996

5.  Status Epilepticus.

Authors:  Elizabeth J. Waterhouse
Journal:  Curr Treat Options Neurol       Date:  2002-07       Impact factor: 3.598

6.  Neuroprotection against excitotoxic brain injury in mice after ovarian steroid depletion.

Authors:  P Elyse Schauwecker; Ruth I Wood; Ariana Lorenzana
Journal:  Brain Res       Date:  2009-02-21       Impact factor: 3.252

7.  AMPA receptor properties are modulated in the early stages following pilocarpine-induced status epilepticus.

Authors:  Isabella Russo; Daniela Bonini; Luca La Via; Sergio Barlati; Alessandro Barbon
Journal:  Neuromolecular Med       Date:  2013-03-15       Impact factor: 3.843

8.  N-methyl-D-aspartic acid receptor activation downregulates expression of δ subunit-containing GABAA receptors in cultured hippocampal neurons.

Authors:  Suchitra Joshi; Jaideep Kapur
Journal:  Mol Pharmacol       Date:  2013-04-12       Impact factor: 4.436

9.  Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus.

Authors:  David E Naylor; Hantao Liu; Jerome Niquet; Claude G Wasterlain
Journal:  Neurobiol Dis       Date:  2013-01-08       Impact factor: 5.996

10.  Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits.

Authors:  Jerome Niquet; Roger Baldwin; Keith Norman; Lucie Suchomelova; Lucille Lumley; Claude G Wasterlain
Journal:  Epilepsia       Date:  2016-08-08       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.